Product Number : 51167-100
Ncivek® (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C
in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously
been treated with interferon-based treatment, including prior null responders, partial responders, and relapsers
Incivek has a slight advantage over Victrelis as the preferred PI in the genotype 1 HCV population. The 100 physicians (gastroenterologists, hepatologists and infectious disease specialists) included in this survey report significantly higher satisfaction with Incivek over Victrelis. Furthermore, physicians perceive that Incivek significantly outperforms Victrelis on the top four most important attributes of ‘high SVR in genotype 1s,’ ‘high SVR in treatment naïve patients,’ ‘high SVR in prior treatment failures’ and ‘supported by clinical data.’ Although both PIs outperform dual therapy on the risk-benefit ratio, Incivek is ranked significantly better than Victrelis in terms of benefits of treatment outweighing the associated risks.